H.C. Wainwright Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $21
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX) and PDS Biotechnology (PDSB)
Noble Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $17
H.C. Wainwright Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $21
PDS Biotechnology Analyst Ratings
Noble Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $17
PDS Biotechnology (PDSB) Receives a Buy From Noble Financial
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
H.C. Wainwright Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $21
Buy Rating Justified: PDS Biotechnology's Versamune HPV Shows Promise in Phase 2 Trials
PDS Biotechnology Analyst Ratings
A. G. P. Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Cuts Target Price to $7
Noble Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $17
PDS Biotechnology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
B.Riley Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $9
Buy Rating Affirmed for PDS Biotechnology Amidst Promising Clinical Developments and Regulatory Progress
H.C. Wainwright Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $21
Optimistic Buy Rating for PDS Biotechnology Amid Promising Versamune HPV Trial Progress and Strategic FDA Alignment
PDS Biotechnology (PDSB) Receives a Buy From Noble Financial
No Data
No Data